Buying Rybelsus in Mexico: what the TikTok version leaves out

What did @quietlyfe actually say?

Elia Harris documented ordering what she calls "Robelsus" (Rybelsus, oral semaglutide) through a Mexican delivery app called Rappy, comparing it to Uber Eats. She paid roughly 2,208 pesos, which she estimates at about $120 USD, for the 3 mg tablet. She framed the whole process as proof of how easy it is to get the medication in Mexico, with zero mention of a prescription, a doctor, or any medical supervision.

She also mentioned previously trying "Fenthermina" (phentermine) without success, which is worth flagging on its own. Phentermine is a Schedule IV controlled stimulant in the US. She's casually cycling through weight-loss drugs with no apparent clinical guidance, which is not a minor detail.

Does the science back this up?

Semaglutide works. That part is not up for debate. The STEP trials (Wilding et al., 2021, New England Journal of Medicine) showed injectable semaglutide producing around 15% body weight reduction over 68 weeks. The oral form, Rybelsus, is less studied for weight loss specifically since it was approved for type 2 diabetes management, not obesity.

Oral semaglutide has significantly lower bioavailability than the injectable version, roughly 1% absorption under ideal fasting conditions (Buckley et al., 2018, Clinical Pharmacokinetics). The 3 mg dose she's starting with is the lowest available tablet strength and is considered a titration dose, not a therapeutic dose for either diabetes or weight loss. Studies like PIONEER 1 (Aroda et al., 2019, Diabetes Care) used doses up to 14 mg for glycemic control. Starting at 3 mg and staying there is unlikely to produce meaningful weight loss results.

What did they get wrong (or right)?

She got the pronunciation mostly wrong but that's forgivable. The bigger issues are clinical, not linguistic.

First, Rybelsus is not approved by the FDA for weight loss. It is approved for type 2 diabetes. Wegovy (injectable semaglutide 2.4 mg weekly) is the weight management-indicated product. Using Rybelsus off-label for weight loss is a real practice, but it carries less supporting evidence and requires a prescriber making that judgment call for a specific patient.

Second, and more seriously, she ordered this medication through a food delivery app with no visible prescription process shown. In Mexico, semaglutide technically requires a prescription under COFEPRIS regulations, though enforcement at the point-of-sale can be inconsistent. The video makes obtaining a GLP-1 drug look equivalent to ordering tacos. That framing is misleading regardless of what local enforcement looks like on the ground.

What she got right: the approximate price conversion was reasonable, and her description of it as a tablet is accurate. Oral semaglutide is genuinely unique among GLP-1 drugs in that format.

What should you actually know?

A few things matter here that the video completely skips. GLP-1 receptor agonists like semaglutide carry real side effect profiles, including nausea, vomiting, gastroparesis risk, and rare but serious risks like pancreatitis. The FDA label includes a boxed warning about thyroid C-cell tumors observed in rodent studies, though causation in humans has not been established.

Starting any GLP-1 drug without baseline labs, a thyroid history check, or a discussion about contraindications is not a wellness hack. It is an unsupervised medical decision. The casual "we'll start tomorrow ladies" ending glosses over the fact that this drug class requires titration, monitoring, and ongoing clinical contact.

The cross-border drug access angle is also not straightforward. Bringing prescription medications into the US from Mexico has legal gray zones that vary by quantity and circumstance. The video implies none of this complexity exists.

Is there anything useful here for viewers?

Honestly, the video does surface a real phenomenon: significant price disparities for semaglutide between the US and Mexico are well-documented and drive medical tourism. A 30-day supply of Rybelsus in the US can run $800 to $1,000 without insurance. The $120 price point she cites reflects a genuine access gap that affects millions of people.

That systemic issue deserves serious discussion. But documenting a prescription drug purchase through a delivery app without any clinical context does not serve viewers who might replicate it. The price point is real. The process she showed is not a model to follow.